Key result
A literature review of 28 cost-of-illness studies for atrial fibrillation revealed highly heterogeneous methodologies and variable annual excess costs, ranging from ~$1,900 to ~$19,000 in the USA.
Why the study?
What are the current cost-of-illness estimates and methodologies for atrial fibrillation?
What are the current cost-of-illness estimates and methodologies for atrial fibrillation?
Cost-of-illness studies for atrial fibrillation show considerable economic consequences but use heterogeneous methodologies, highlighting the need for standardized approaches focusing on subpopulations and treatment mixes.
Variable AF cost estimates warrant caution in economic models; leaves open standardized methodologies for subpopulations.
Atrial fibrillation (AF) is the most common heart rhythm arrhythmia, which has considerable economic consequences. This study aims to identify the current cost-of-illness estimates of AF; a focus was put on describing the studies' methodology. A literature review was conducted. Twenty-eight cost-of-illness studies were identified. Cost-of-illness estimates exist for health insurance members, hospital and primary care populations. In addition, the cost of stroke in AF patients and the costs of post-operative AF were calculated. The methods used were heterogeneous, mostly studies calculated excess costs. The identified annual excess costs varied, even among studies from the USA (∼US$1900 to ∼US$19,000). While pointing toward considerable costs, the cost-of-illness studies' relevance could be improved by focusing on subpopulations and treatment mixes. As possible starting points for subsequent economic studies, the methodology of cost-of-illness studies should be taken into account using methods, allowing stakeholders to find suitable studies and validate estimates.
No takes yet. Share an insight, caveat, or question.
Christian Becker (2014) conducted a review in Atrial fibrillation. A literature review of 28 cost-of-illness studies for atrial fibrillation revealed highly heterogeneous methodologies and variable annual excess costs, ranging from ~$1,900 to ~$19,000 in the USA.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: